Cryptocurrency & Digital Assets

A historic $100M C-PACE loan funds a massive AI campus in Kansas City's iconic Star building, merging green finance with high-tech urban renewal.

The wellness firm secured a cash infusion by repricing options, a move that provides vital funds for its Zola brand but raises questions about dilution.

The legendary Southern chicken chain has landed in Brooklyn with a 24-hour drive-thru, testing its iconic flavors in NYC's competitive food scene.

NYU Langone and tech firm Tempus are launching a new protocol using serial DNA sequencing and AI to create hyper-personalized cancer treatments.

Petco is refinancing $1.5B in debt to extend maturities while reaffirming its financial outlook. Is this a sign of strength or underlying strain?

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

FDA clears a novel two-part immunotherapy that paints solid tumors with a synthetic target, unleashing a powerful CAR T-cell attack in a new clinical trial.

Promising new 96-week data shows Vir's therapy could redefine care for severe hepatitis delta, as its oncology pipeline and financial runway also advance.

The insurance giant landed a major credit facility, calming investor nerves and doubling down on its fast-growing pharmacy and healthcare services arm.

With preliminary Q1 revenue of $103.7M, Twist Bioscience beats forecasts, setting a bullish tone ahead of its full earnings report on February 2nd.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

Interim data suggests LX2020 is well-tolerated and may reduce dangerous arrhythmias by targeting the root cause of PKP2-associated cardiomyopathy.

Backed by Purolator, a massive network expansion by Williams Pharmalogistics aims to reshape Canada's temperature-controlled medical delivery landscape.

As the ISS era ends, Mitsubishi Corporation's major investment in Starlab Space secures Japan's future in orbit and heats up the commercial space race.

Adaptive posted a 55% revenue surge in 2025, fueled by its clonoSEQ cancer test. Now, the firm is charting a clear course to company-wide profitability.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

With FDA alignment for its rapid postpartum depression therapy and new trials for anxiety, Reunion Neuroscience is pioneering a new era of mental health.

KEY Investment Partners acquires BellRock Brands' portfolio out of receivership, launching MM Brands with Joe Bayern to lead a wellness-focused revival.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?